PMC/PubMed Indexed Articles
Indexed In
- Academic Journals Database
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- CiteFactor
- Scimago
- Ulrich's Periodicals Directory
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- MIAR
- University Grants Commission
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Economic implications of adopting high cost breakthrough technologies- PCSK9 inhibitors as a case study
2nd International Conference & Expo on Biopharmaceutics and Biologic Drugs
September 14-16, 2016 San Antonio, USA
Ronen Arbel
Sapir College and Ben-Gurion University of the Negev, Israel
Posters & Accepted Abstracts: J Bioequiv Availab
Abstract:
The proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have shown a significant benefit in reducing the levels of low-density lipoprotein cholesterol and early evidence of improving patient outcomes by reducing the rate of major adverse cardiovascular events (MACE) compared to standard statin therapy. Based on these trials, the FDA approved two PCSK9i drugs for the treatment of hyperlipidemia. PCSK9i present an extraordinary challenge for healthcare payers. This is the first major case in which a specialty biologic drug is approved for a relatively common condition. The entire intended population for use according to the approved FDA indications is estimated at more than 9.3 million patients in the US. The annual budget needed to treat this population would be more than $130 billion. Performing a traditional cost-effectiveness analysis (CEA) using the current limited data is challenging and requires modeling and many assumptions. We therefore built a unique model with straightforward economic implications, based on the limited available data at present. The cost of preventing any one MACE would be $2,004,918 and the cost of preventing one death would be $8,777,518. These figures are one hundred fold higher than the cost of curing one Hepatitis C (HPC) patient with novel HPC drugs (~$84,000). If upcoming outcome trials will demonstrate similar rates of MACE prevention, it seems that at current prices, using these drugs to improve cardiovascular outcomes would not be affordable for many healthcare systems. The model developed could be relevant to any high cost breakthrough Technologies.
Biography :
Email: ronen.arbel@gmail.com